Parkman Healthcare Partners

Gregory Martinez is the Managing Member and Chief Investment Officer. The partnership structure includes five named partners — Martinez, Michael Elgort, Jeremy Chase, Logan Unland, and Matthew Ostrup — but the firm’s website does not specify whether decisions are made by Martinez alone or by an investment committee that includes the other partners.

Parkman describes its process as thematic growth investing combined with risk management and protection. The firm targets value inflection points as standards of care evolve, applying a fundamental research process across biotech, pharma, medical devices, diagnostics, life science research, and services. No portfolio company names are publicly disclosed.

Three of the five named partners hold MDs, and two of the three recently hired analysts are also physicians. The firm does not publish a formal clinical advisory board structure, so the clinician-investors likely perform therapeutic-area diligence directly rather than outsourcing it to external key opinion leaders.

No. The firm does not publicly disclose assets under management, specific fund vehicles, or discrete deployment figures. Employee ownership is stated, but there is no mention of closed-end fund structures, open-ended vehicles, or separate managed accounts on the public website.

Parkman’s public materials do not address co-investment policy. The firm’s employee-owned structure and small professional headcount — 12 total — suggest it likely writes its own checks, but no explicit posture on syndication or co-underwriting with other funds is disclosed.

The firm states it seeks out innovations globally, though its listed office footprint is entirely domestic US. Without disclosed portfolio companies, it is impossible to confirm whether deployed capital extends to ex-US healthcare companies or remains concentrated in US-based small- and mid-cap names.

Parkman is 100% employee-owned. The website does not specify an ownership structure beyond that, but the five named partners likely hold the majority of equity. There is no parent company, external financial sponsor, or disclosed succession plan detailed in public materials.